Business Context and Reporting Period
Company: The Kroger Co.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Third quarter ended November 9, 2024 (12 weeks) and the first three quarters ended November 9, 2024 (40 weeks).
Business Overview: Kroger operates as a large accelerated filer in the omnichannel retail sector, focusing on supermarket, fuel, and health and wellness businesses. The period was significantly impacted by the termination of the proposed merger with Albertsons Companies, Inc.
Key Financial Metrics
| Metric (in millions, except per share) | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Sales | $33,634 | $33,957 | $112,815 | $112,975 |
| Operating Profit | $828 | $912 | $2,937 | $1,902 |
| Net Earnings (Attributable to Kroger) | $618 | $646 | $2,031 | $1,428 |
| Diluted EPS | $0.84 | $0.88 | $2.77 | $1.95 |
| Operating Cash Flow (YTD) | N/A | $4,390 | $4,868 | |
| Total Debt (Nov 9, 2024) | $22,601 | N/A | ||
| Cash & Temporary Investments (Nov 9, 2024) | $13,358 | N/A |
Note: Total debt includes current and long-term portions of obligations under finance leases. Cash balance reflects proceeds from senior notes issuance.
Material Changes vs. Prior Period
- Sales: Total sales decreased 1.0% in Q3 2024 compared to Q3 2023, primarily due to a decline in fuel sales (-18.8%) and the sale of the Kroger Specialty Pharmacy business. However, identical sales excluding fuel increased 2.3% in Q3 and 1.2% YTD, driven by growth in total and loyal households and Health and Wellness sales.
- Profitability: Operating profit decreased 9.2% in Q3 2024 ($828M vs $912M) but increased 54.4% YTD ($2.9B vs $1.9B). The YTD increase was significantly aided by the absence of the $1.4B opioid settlement charge recorded in Q2 2023.
- Net Earnings: GAAP net earnings decreased 4.3% in Q3 2024 but surged 42.2% YTD. Adjusted net earnings (excluding merger costs, investment gains/losses, and pharmacy sale impacts) increased 3.0% in Q3 and decreased 2.1% YTD.
- Debt & Liquidity: Total debt increased by approximately $10.4 billion to $22.6 billion as of November 9, 2024, driven by the issuance of $10.5 billion in senior notes intended to fund the Albertsons merger. Consequently, cash and temporary cash investments rose to $13.4 billion.
- Dividends: Dividends paid increased 10.0% in Q3 and 11.1% YTD compared to the prior year periods.
Guidance, Outlook, and Material Events
- Merger Termination: On December 11, 2024, following a preliminary injunction by a federal court and a permanent injunction by a Washington state court, Kroger terminated its merger agreement with Albertsons. The company asserts it has no obligation to pay the $600 million termination fee due to Albertsons' failure to comply with covenants.
- Debt Redemption: In response to the merger termination, Kroger initiated the redemption of $4.7 billion in senior notes (SMR Notes) issued in August 2024, scheduled for December 18, 2024, at 101% of principal plus accrued interest.
- Share Repurchase Program: On December 11, 2024, the Board terminated the paused $1.0 billion repurchase program and authorized a new $7.5 billion program. Approximately $5.0 billion is expected to be executed via an accelerated share repurchase program.
- Asset Sale: Kroger completed the sale of its Specialty Pharmacy business to Elevance Health for $464 million in October 2024, recognizing a $79 million gain. This divestiture reduced annualized sales by approximately $3 billion but improved gross margin rates.
- Opioid Settlement: The company is proceeding with a nationwide opioid settlement framework, with payments expected to begin in 2025. A liability of $1.4 billion was accrued in 2023.
- Outlook: Management expects to maintain an investment-grade debt rating and a net total debt to adjusted EBITDA ratio target of 2.30 to 2.50. The company remains committed to growing dividends and returning excess cash to shareholders.
Investor Verification Checklist
- Debt Structure: Verify the impact of the $4.7 billion note redemption on the balance sheet and interest expense in the subsequent quarter.
- Merger Litigation: Monitor the status of the lawsuit filed by Albertsons seeking the $600 million termination fee and potential damages.
- Capital Allocation: Track the execution of the new $7.5 billion share repurchase program, specifically the accelerated portion.
- Operational Metrics: Confirm the sustainability of identical sales growth (excluding fuel) amidst competitive pricing pressures and the loss of pharmacy sales volume.
- Liquidity Position: Assess the utilization of the $13.4 billion cash balance for debt paydown, dividends, and repurchases versus operational needs.